Scroll Top

Launching our enhanced treatment pathways in NSCLC

Posted by James Hutton

After a lot of hard work by our dedicated teams, Springer Healthcare IME is pleased to announce the launch of new resources for medical and radiation oncologists, based on approved guidelines in three global regions – Europe, Asia and North America (coming soon). These resources are called enriched treatment pathways.

The treatment pathways map out the progressive stages of non-driver non-small cell lung cancer (NSCLC) and provide information for oncologists about how to treat patients at each stage, as the disease progresses.

It is an interactive, visual resource, but embedded with layers of data and further content within the framework of a treatment pathway graphic. With the help of an overseeing expert author in each of the three regions, the aim of this program is to provide a data-driven guide, built as an interactive graphic representing the locally approved guidelines, with published data and expert insight to help aid clinical decision making.

Built to allow for responsive design for use on different media, this is our first product of this kind and is intended to be a ‘go-to’ resource for oncology healthcare professionals. It is enriched with information and the latest research data, in an easily navigatable format, so hopefully it will become a repeated and trusted educational reference tool for our learners.

The types of content that can be found in the pathways include:

  • Expert audio commentary clips
  • Expert video commentary clips from the regional expert author leading each pathway
  • Key clinical trial summaries
  • Video footage from our related IME symposium at the IASLC 20th World Conference on Lung Cancer (WCLC 2019)
  • Hyperlinks to published journal articles
  • Carefully created explanations behind treatment stages for NSCLC
  • Split sub-paths for squamous and non-squamous NSCLC

Due to the nature of this resource, it is intended to be widely used and there will be periodical updates, if necessary, to encapsulate guideline adaptations over a 12-month period. We are pleased these resources are being hosted on our sister website Medicine Matters oncology and we are working closely to ensure dissemination to our targeted oncology audience for each pathway.

For further information in independent medical education (IME) programs we have in development, please contact

Educational grant disclosure: This activity is supported by an education grant from Eli Lilly and Company.